Additional in vivo studies are needed to gain a better understanding of the role of α-tropomyosin in atherosclerosis and angiogenesis, as well as to examine the potential of TPM1 as a candidate therapy target for proinflammatory vascular disorders. The gene discussed is TPM1; the disease is atherosclerosis.